Article

pT classification, grade, and vascular invasion as prognostic indicators in urothelial carcinoma of the upper urinary tract

Institute of Pathology, Medical University Graz, Graz, Austria.
Modern Pathology (Impact Factor: 6.36). 03/2006; 19(2):272-9. DOI: 10.1038/modpathol.3800529
Source: PubMed

ABSTRACT Clinicopathologic features predictive of patient outcome in upper urinary tract urothelial carcinoma are not well defined. The aim of this study was to assess the role of pT classification, tumor grade, and vascular invasion in predicting metastasis-free survival. A total of 190 consecutive invasive upper urinary tract urothelial cancers operated between 01/1984 and 12/2004 were re-evaluated with respect to pT classification, tumor grade (according to the three-tiered WHO 1973 and the recent two-tiered grading system following the WHO/ISUP consensus classification), as well as presence of lymph and/or blood vessel invasion. Prognostic impact was analyzed using the Kaplan-Meier method and the Log-Rank test. For multivariate testing, a Cox's proportional hazards regression model was used. pT1 was present in 81 (43%), pT2 in 29 (15%), pT3 in 73 (38%), and pT4 in seven (4%) cases. There were 12 (6%) G1, 96 (51%) G2, and 82 (43%) G3 tumors or 84 (44%) low-grade and 106 (56%) high-grade tumors according to the two-tiered system. The presence of vascular invasion in 72/190 (38%) tumors was associated with high pT classification (P<0.001) and high tumor grade (P<0.001). Disease progression occurred in 39% of patients, with 5- and 10-year metastasis-free survival rates of 56 and 45%, respectively. On univariate analysis, all investigated parameters showed prognostic significance. The negative influence of vascular invasion on patient outcome was strikingly strong in high pT classification and high-grade cancers. On multivariate analysis, pT classification (P<0.001) and vascular invasion (P<0.001) proved to be independent prognostic factors, whereas tumor grade according to the two-tiered system missed statistical significance (P=0.06). In conclusion, pT classification and vascular invasion are independent prognostic factors with respect to metastasis-free survival and should be used to guide adjuvant therapy strategies in affected patients. Presence (or absence) of vascular invasion should be commented upon separately in the pathology report.

Download full-text

Full-text

Available from: Georg C Hutterer, Feb 03, 2015
0 Followers
 · 
139 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Open radical nephroureterectomy (O-RNU) has been the gold standard for the treatment of upper urinary tract urothelial carcinoma (UUT-UC) for decades. With the advances in laparoscopic techniques and endourologic procedures, this concept has been increasingly challenged. Oncologic outcome prediction is mainly based on stage and grade. With progress in medical treatment, adjuvant therapies may gain importance in the future. This review assesses the values of the variety of available treatments as well as prognostic factors that may become relevant regarding patient selection for future adjuvant treatment trials. We performed a systematic literature research using MEDLINE with emphasis on open surgical, laparoscopic, and endourologic (ureteroscopic or percutaneous) techniques and prognostic contents. Overall, no evidence level 1 information from prospective randomised trials is available for treatment of UUT-UC. Laparoscopic radical nephroureterectomy (L-RNU) is increasingly challenging open surgery. Currently, L-RNU should be reserved for low-stage, low-grade tumours. Ureteroscopy and percutaneous nephron-sparing techniques show favourable survival data but high local recurrence rates. Regarding prognosis, estimation of outcome still relies mainly on stage and grade because no additional parameters have been introduced in a routine clinical setting. O-RNU still represents the gold standard for the treatment of UUT-UC. The laparoscopic approach is not yet standard of care and should be reserved for low-stage, low-grade tumours. Endourologic nephron-sparing treatments are still experimental in elective indications due to high local recurrence rates. For prognosis, no parameters in addition to stage and grade have been standardised.
    European Urology 05/2008; 53(4):720-31. DOI:10.1016/j.eururo.2008.01.006 · 12.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Das Urothelkarzinom des oberen Harntrakts (UTUC) ist eine seltene, aber potentiell tödliche Erkrankung. Eine akkurate Risikostratifizierung von UTUC-Patienten ist aufgrund eines schwierigen klinischen Stagings eine Herausforderung. Die Identifizierung von Risikofaktoren kann zu einer individualisierten Patientenberatung und Therapieentscheidung beitragen und somit den Erkrankungsverlauf beeinflussen. Ein nicht-systematisches PubMed/Medline-Literaturreview wurde durchgeführt, um klinische und pathologische Risikofaktoren, sowie urinbasierte prädiktive Marker zu identifizieren. Obgleich in den vergangenen 5 Jahren zahlreiche Studien über mögliche Risikofaktoren beim UTUC publiziert worden sind, so ist die diesbezügliche Evidenz jedoch weiterhin limitiert. Derzeit liegen keine prospektiven, randomisierten Studienergebnisse vor, die eine ausreichende Evidenz bedingen würden. Die radikale Nephroureterektomie stellt die Standardtherapie des muskelinvasiven und Hochrisko-UTUC dar. Zahlreiche klinische und pathologische Faktoren (z. B. Tumorstadium und -grad, Alter, präoperative Hydronephrose, lymphovaskuläre Invasion, Tumornekrose und -architektur, Verzögerung zwischen Diagnose und endgültiger Therapie) sind mit dem Erkrankungsverlauf assoziiert. Die Urinzytologie und Urinanalyse mittels Fluoreszenz-in-situ-Hybridisierung stellen derzeit die gängigsten Urinmarker beim UTUC dar. Prospektive randomisierte Studien werden dringend benötigt, um neue Risikofaktoren zu identifizieren und die Effizienz gegenwärtiger zu bestätigen. Die Verwendung identifizierbarer Risikofaktoren in multivariablen Vorhersagemodellen kann bei Therapieentscheidungen hinsichtlich Art der Operation, Durchführung einer Lymphadenektomie oder perioperativen Chemotherapie behilflich sein.
    Der Urologe 09/2012; 51(9). DOI:10.1007/s00120-012-2911-9 · 0.44 Impact Factor